

Enhancement of the surface expression of G protein-coupled receptors

Jill H. Dunham and Randy A. Hall

Department of Pharmacology, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA

G protein-coupled receptors (GPCRs) mediate physiological responses to a diverse array of stimuli and are the molecular targets for numerous therapeutic drugs. GPCRs primarily signal from the plasma membrane, but when expressed in heterologous cells many GPCRs exhibit poor trafficking to the cell surface. Multiple approaches have been taken to enhance GPCR surface expression in heterologous cells, including addition/deletion of receptor sequences, co-expression with interacting proteins, and treatment with pharmacological chaperones. In addition to providing enhanced surface expression of certain GPCRs in heterologous cells, these approaches have also shed light on the control of GPCR trafficking *in vivo* and in some cases have led to new therapeutic approaches for treating human diseases that result from defects in GPCR trafficking.

Introduction

Most vertebrate genomes encode approximately 1000 G protein-coupled receptors (GPCRs), making them the largest class of cell-surface receptors. These receptors are activated by various extracellular ligands (including hormones, neurotransmitters, drugs and sensory stimuli) and couple to intracellular G proteins, which mediate many of the effects on cellular physiology downstream of receptor activation [1]. Because of their location at the cell surface and the discrete tissue expression patterns of many members of this family, GPCRs are excellent targets for therapeutics, with nearly half of all current prescription drugs acting through GPCRs [2].

Since GPCRs are such valuable drug targets, there are numerous ongoing efforts to identify novel compounds that act as agonists, antagonists or allosteric modulators of GPCRs. These studies typically involve expression of a given GPCR in heterologous cells, measurement of a downstream readout of receptor activity and screening of large libraries of compounds for effects on activation of the receptor of interest. However, because most GPCR ligands are not membrane-permeable these methods depend entirely on expression of the receptor at the cell surface so that the ligand has full access to its binding site. Thus, a major problem for drug discovery efforts is the poor trafficking to the plasma membrane of many GPCRs when expressed in heterologous cells.

As with all transmembrane proteins, plasma membrane localization of GPCRs depends on efficient delivery to the plasma membrane [3]. Many factors are involved in receptor delivery to the plasma membrane. The endoplasmic reticulum (ER) is the primary location for protein folding

and maturation, which must proceed properly for receptor release to the Golgi and eventually to the plasma membrane. Treatments that globally disrupt ER function, including modulation of heat shock proteins and inhibition of glycosylation, can lead to altered trafficking of GPCRs and many other proteins, but such global approaches have been reviewed elsewhere [4] and are not addressed here. This review focuses on approaches used over the past two decades to specifically enhance the trafficking of particular GPCRs to the plasma membrane, including addition of sequences that improve receptor trafficking, removal of sequences that impair receptor trafficking, co-expression with receptor-interacting proteins and treatment with drugs. Examples of these four distinct approaches are discussed in the sections below.

Addition of sequences

One major approach used to enhance plasma membrane expression of GPCRs in heterologous cells is the addition of sequences to the receptors. The first example of this approach was the engineering of an artificial signal sequence onto the N-terminus of the β_2 -adrenoceptor [5], which resulted in a several-fold increase in insertion of the receptor into the plasma membrane. Artificial signal sequences were subsequently used to enhance the surface expression of other GPCRs, notably the CB1 cannabinoid receptor [6,7]. It is presumed that signal sequences facilitate receptor interactions with the signal recognition particle (SRP) and SRP receptor, which promote more efficient receptor targeting through the ER and membrane insertion [8].

Sequences other than traditional signal sequences have also been grafted onto the N-termini of certain GPCRs to enhance their surface expression. For example, in the case of olfactory receptors (ORs), which are the largest subfamily of GPCRs with more than 300 members in humans and approximately 1000 members in rodents, a variety of N-terminal sequences have been used to enhance plasma membrane targeting. Most ORs are inefficiently trafficked to the plasma membrane in heterologous cells [9], but addition of N-terminal sequences from the serotonin 5-HT₃ receptor [10,11] or rhodopsin [12,13] markedly enhanced heterologous surface expression of many ORs. The use of ORs with modified N-termini has yielded significant advances over the past few years in defining the pharmacological and signaling properties of this large and diverse family of GPCRs [9].

Although most sequences that enhance GPCR trafficking have been added to the N-terminal region of the

receptors, there are also examples of C-terminal additions that enhance receptor surface expression. For example, the rat gonadotropin-releasing hormone receptor (GnRHR) has a very short C-terminal tail and exhibits poor surface expression in most heterologous cells, whereas the catfish GnRHR has a much longer C-terminal region and exhibits robust surface expression in most cell types [14]. Addition of the catfish GnRHR C-terminus to rat GnRHR results in a striking improvement in the surface trafficking of the rat version of the receptor [14]. Interestingly, the GnRHR C-terminus is highly variable between species, suggesting that this receptor region might have been subject to intense evolutionary selection pressure as a mechanism for controlling GnRHR expression and functionality [15].

Deletion of sequences

A second major approach used to enhance the surface expression of certain GPCRs is the deletion of sequences that result in either ER retention or misfolding of the receptors. For example, following cloning of the γ -aminobutyric acid receptor GABA_BR1 [16], it was widely recognized that the receptor was poorly trafficked and largely non-functional when expressed in heterologous cells [17]. Truncation of the GABA_BR1 C-terminus or mutation of a specific C-terminal motif (RSRR) relieved ER retention of GABA_BR1 and led to robust plasma membrane expression of the receptor [18–20]. Interestingly, the critical RSRR motif on the GABA_BR1 C-terminus is similar to ER retention motifs identified on certain ion channels and other transmembrane proteins [21]. However, despite the improved trafficking of the GABA_BR1 RSRR mutant, this receptor could not couple to G proteins unless it was co-expressed with a related receptor, GABA_BR2, which seems to be a required heterodimer partner of GABA_BR1 for formation of functional GABA_B receptors [20,22–24].

Analogous to the removal of C-terminal sequences from GABA_BR1, removal of N-terminal sequences from GPCRs was effective in enhancing receptor surface expression in some cases. For example, truncation of 79 amino acids from the N-terminus of the α_{1D} -adrenoceptor (α_{1D} -AR) dramatically enhanced expression of receptor binding sites [25] and plasma membrane localization [26]. By contrast, grafting of the α_{1D} -AR N-terminus onto α_{1A} -AR or α_{1B} -AR markedly impaired surface expression of these receptors in heterologous cells [26], suggesting that the α_{1D} -AR N-terminus either has an ER retention motif or has difficulty in folding properly. Similar findings were observed for the CB1 cannabinoid receptor, for which it was shown that truncation of the N-terminus of the receptor greatly enhanced receptor surface expression [7]. It has been shown for both α_{1D} -AR and CB1 that the N-terminal truncations that enhance trafficking do not alter ligand binding [7,26] and that the truncated mutants are therefore useful for achieving enhanced surface expression of functional receptors in heterologous cells.

A key reason why some orphan GPCRs are still orphans at present is because their poor surface expression in heterologous cells has greatly hampered ligand-screening efforts. However, application of the approaches described above (addition or subtraction of sequences) has in some cases already resulted in orphan receptors that are

trafficked more efficiently to the plasma membrane and are therefore more suitable for functional experiments. For example, GPRC6A is an orphan receptor that exhibits poor surface expression in heterologous cells [27]. Given its similarity to metabotropic glutamate receptors and GABA_B receptors, it has been assumed that the N-terminus of GPRC6A is most likely the primary site of ligand binding. GPRC6A is also very similar to a goldfish receptor known as 5.24 that is trafficked well to the plasma membrane in heterologous cells, and thus a chimera was created in which the N-terminus of GPRC6A was fused to the transmembrane and C-terminal regions of the 5.24 receptor [28]. This mutant receptor, lacking the transmembrane and C-terminal regions of wild-type GPRC6A, exhibited efficient trafficking to the plasma membrane and enabled identification of positively charged amino acids, such as arginine, as putative ligands for GPRC6A [28].

Co-expression with partners

Most, if not all, GPCRs act primarily at the plasma membrane in the native cell types in which they are endogenously expressed. If a given GPCR exhibits poor surface trafficking in heterologous cells, a common explanation is that the heterologous cells must lack one or more receptor-interacting partners that normally promote proper folding and trafficking of the receptor in native cells. Thus, over the past two decades there has been intense interest in identifying GPCR-associated proteins [29–31] and many of the interactions identified have indeed helped to explain cell-specific differences in GPCR trafficking.

A major class of interactions that can greatly promote GPCR surface expression in some cases is interactions with other GPCRs (also known as heterodimerization or heterooligomerization) [32]. For example, as noted above, co-expression of GABA_BR1 with GABA_BR2 results in massive enhancement of GABA_BR1 surface expression [33]. One consequence of this heterodimerization is believed to be masking of the aforementioned ER retention motif present on the GABA_BR1 C-terminus [19], providing an example of how two distinct approaches (deletion of a sequence and co-expression with an appropriate partner to mask a sequence) can in some cases enhance the surface targeting of a given GPCR via related mechanisms. There is strong evidence that the interaction between GABA_BR1 and GABA_BR2 is also essential for GABA_BR1 trafficking *in vivo*, because the brains of GABA_BR2 knockout mice exhibit a striking redistribution of GABA_BR1 and substantial loss in GABA_B receptor functional activity [34].

In addition to GABA_B receptors, a number of other GPCRs have been found to exhibit enhanced surface expression in heterologous cells on co-expression and association with other GPCRs [32]. For example, the aforementioned α_{1D} -adrenoceptor assembles with the α_{1B} -adrenoceptor [35,36] and β_2 -adrenoceptor [37] in a manner that strongly promotes α_{1D} -AR surface trafficking in heterologous cells. Similarly, co-assembly of some ORs with certain members of the adrenoceptor and purinoceptor families can enhance OR surface expression in heterologous cells [38,39]. Along these same lines, co-expression of the taste receptor T1R1 with its related receptors T1R2 and T1R3 results in greatly enhanced functionality that is

believed to correlate with improved surface expression, although the work undertaken in this area so far has focused more on assessing changes in receptor activity and pharmacology following heterodimerization than on addressing any changes in receptor trafficking [40].

It has been found that a variety of other interactions besides receptor–receptor associations strongly regulate GPCR trafficking and surface expression. Some of these GPCR-interacting partners have been identified in genetic screens. For example, in screens for mutations that affect visual transduction in *Drosophila*, the cyclophilin-related protein NinaA was identified as a rhodopsin partner required for rhodopsin folding and transport [41,42]. Subsequent work revealed that the vertebrate homolog of NinaA, RanBP2, associates with vertebrate opsins to regulate their folding, trafficking and surface expression [43]. Similarly, screens for mutations that affect chemosensory signaling in *Caenorhabditis elegans* identified the protein odorant response abnormal 4 (ODR-4), which was shown to associate with certain olfactory receptors [44,45]. It is not known, however, if the vertebrate ortholog of ODR-4 plays a comparable role for any vertebrate receptors [46]. Other GPCR-interacting partners that promote receptor trafficking include GEC1, which promotes surface expression of mammalian κ -opioid [47] and prostaglandin EP3 receptors [48], RACK1, which enhances trafficking of thromboxane A₂ receptors [49], Usp4, which increases plasma membrane expression of adenosine A_{2A} receptors [50], ATBP50, which regulates the transport of angiotensin AT₂ receptor to the cell surface [51], and DRIP78, which enhances surface expression of angiotensin II AT₁ receptors [52].

A variety of transmembrane proteins, including receptor activity modifying proteins (RAMPs), receptor transporting proteins (RTPs), receptor expression enhancing proteins (REEPs), melanocortin receptor accessory proteins (MRAPs) and the M10 family of major histocompatibility (MHC) proteins, have been identified during the past decade as GPCR-interacting proteins that promote the surface expression of specific subsets of GPCRs. The RAMPs were first identified as key regulators of the trafficking and functionality of the calcitonin receptor-like receptor (CRLR), an orphan receptor that was difficult to study until the realization that associations with RAMPs were required for its efficient plasma membrane localization [53]. The three members of the RAMP family are now known to interact with several class B GPCRs, as well as a class C GPCR, the calcium-sensing receptor [54], to influence receptor trafficking and pharmacology [55]. The RTP and REEP proteins were first identified in screens for proteins that enhance OR functionality [56]. RTP1 and RTP2 are selectively expressed in the olfactory epithelium [56] and their roles in controlling OR trafficking have shed light on the underlying reasons why ORs are efficiently targeted to the plasma membrane in olfactory sensory neurons but not in heterologous cells. Other members of the RTP and REEP families have wider tissue distribution patterns and have been shown to promote the surface expression of T2R bitter taste receptors [57] and μ - δ opioid receptor heterodimers [58] in heterologous cells. MRAP and MRAP2 have been shown to associate with the mel-

anocortin 2 receptor (MC2R) and dramatically enhance surface expression of this receptor in a variety of cells [59–62]. Naturally occurring mutations to MRAP cause defects in the trafficking and functionality of MC2R, resulting in an inherited disorder known as familial glucocorticoid deficiency type 2 [59]. MRAPs have also been shown to associate with MC3R and MC4R to reduce the signaling activity and/or surface expression of these receptors [63], so MRAP effects on receptor functionality appear to be receptor-specific. Finally, V2R vomeronasal receptors were difficult to study in heterologous cells until the finding that co-expression and interactions with M10 MHC molecules and β_2 -microglobulin were capable of dramatically enhancing V2R surface expression in heterologous cells [64].

Treatment with pharmacological chaperones

Studies have identified a number of naturally occurring GPCR mutations that cause human disease by impairing normal receptor trafficking. The approaches described above for enhancing the surface targeting of GPCRs – addition of sequences, deletion of sequences and co-expression with partners – can be useful in enhancing the surface expression of GPCRs in heterologous cells, but these approaches are not likely to be useful in a clinical setting without further significant advances in gene therapy technology. Thus, there has been tremendous interest over the past few years in identifying small molecules that can bind to poorly trafficked, disease-causing GPCRs to enhance the surface expression and functionality of these receptors. Such molecules are often referred to as pharmacological chaperones, pharmacochaperones or pharmacoperones [65,66].

An example of the potential utility of pharmacological chaperones comes from work on nephrogenic diabetes insipidus (NDI), a rare X-linked disease characterized by loss of anti-diuretic response to the hormone arginine-vasopressin that results in an inability to concentrate urine. NDI has been linked to a variety of mutations in vasopressin V₂ receptors (V₂Rs), with the majority of these mutations causing V₂R to be retained in the ER and degraded [67]. Treatment of cells with certain membrane-permeant V₂R antagonists restores cell surface expression of ER-retained V₂R mutants [65,68–70]. These results are attributed to binding of the antagonists to the already misfolded V₂R in the ER, resulting in stabilization of receptor structure and trafficking of V₂R to the plasma membrane. Clinical studies have indeed provided proof-of-concept evidence that vasopressin receptor-targeted pharmacological chaperones can have beneficial effects in patients suffering from NDI [71].

Retinitis pigmentosa (RP) is another disease caused by mutations to a GPCR. Characterized by progressive photoreceptor degeneration and eventual retinal dysfunction, RP has been linked to a number of mutations in various gene products encoding nearly all of the components of the visual signaling pathway, including rhodopsin [72]. Mutations in the gene encoding rhodopsin are observed in one particular form of RP, autosomal dominant RP, and result in a mutated receptor that is retained intracellularly with no 11-*cis*-retinal binding. The most common mutation of this type is P23H [73–75]. P23H rhodopsin mutants can be rescued by treatment of cells with an 11-*cis*-retinal

analog, 11-*cis*-ring-retinal, resulting in restoration of receptor surface expression [76] in a manner that is analogous to the rescue of V₂R surface expression by V₂R antagonists described above.

A third example of disease-causing mutations that affect GPCR trafficking comes from studies on GnRHR mutations that can result in hypogonadotropic hypogonadism (HH), a condition characterized by disrupted sexual maturation. The GnRHR mutations that cause HH result in misfolded receptors that are not properly targeted to the plasma membrane. As in the above-described cases of pharmacological chaperones for V₂R and rhodopsin, it has been found that certain GnRHR antagonists are capable of rescuing mutant GnRH receptors by restoring the surface expression and signaling activity of the mutant receptors [66,77,78].

Conclusion and perspectives

The various approaches described in this review – addition and deletion of receptor sequences, co-expression with partners and treatment with pharmacological chaperones – have been useful in enhancing the plasma membrane expression of various GPCRs in heterologous cells (Figure 1). Such enhanced surface expression of receptors can greatly facilitate drug discovery efforts focused on GPCRs as therapeutic targets. In addition to providing insights into how to improve receptor surface trafficking in heterologous cells, studies in this area have also shed tremendous light on the regulation of the receptors *in vivo*. Knockout studies for many of the receptor-associated proteins described above revealed that these proteins are critical for receptor regulation in native tissues. Moreover, recent advances in the characterization of pharmacological chaperones that enhance receptor trafficking in heterologous cells can be directly translated to the clinic and might be useful in future treatments for a number of human diseases.




Figure 1. Approaches for enhancement of GPCR surface expression. When expressed in heterologous cells, many GPCRs exhibit poor plasma membrane trafficking, which can be enhanced using a variety of methods. For instance, addition or deletion of receptor sequences can in some cases greatly improve receptor surface expression. In other situations, co-expression with specific receptor-interacting partners can strongly promote proper surface trafficking. These receptor-interacting partners can either be transmembrane proteins, as illustrated in this schematic figure, or cytoplasmic proteins that associate with intracellular domains of the receptor. Finally, pharmacological chaperones can release certain misfolded receptors from the endoplasmic reticulum and enhance their trafficking to the plasma membrane.

Acknowledgments

The authors' research is supported by grants from the National Institutes of Health.

References

- Hill, S.J. (2006) G-protein-coupled receptors: past, present and future. *Br. J. Pharmacol.* 147 (Suppl. 1), S27–S37
- Conn, P.J. *et al.* (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. *Nat. Rev. Drug Discov.* 8, 41–54
- Tan, C.M. *et al.* (2004) Membrane trafficking of G protein-coupled receptors. *Annu. Rev. Pharmacol. Toxicol.* 44, 559–609
- Brodsky, J.L. (2007) The protective and destructive roles played by molecular chaperones during ERAD (endoplasmic-reticulum-associated degradation). *Biochem. J.* 404, 353–363
- Guan, X.M. *et al.* (1992) Enhancement of membrane insertion and function in a type IIIb membrane protein following introduction of a cleavable signal peptide. *J. Biol. Chem.* 267, 21995–21998
- McDonald, N.A. *et al.* (2007) An essential role for constitutive endocytosis, but not activity, in the axonal targeting of the CB1 cannabinoid receptor. *Mol. Pharmacol.* 71, 976–984
- Andersson, H. *et al.* (2003) Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. *Mol. Pharmacol.* 64, 570–577
- Hegde, R.S. and Kang, S.W. (2008) The concept of translocational regulation. *J. Cell Biol.* 182, 225–232
- Bush, C.F. and Hall, R.A. (2008) Olfactory receptor trafficking to the plasma membrane. *Cell. Mol. Life Sci.* 65, 2289–2295
- Wellerdieck, C. *et al.* (1997) Functional expression of odorant receptors of the zebrafish *Danio rerio* and of the nematode *C. elegans* in HEK293 cells. *Chem. Senses* 22, 467–476
- Wetzel, C.H. *et al.* (1999) Specificity and sensitivity of a human olfactory receptor functionally expressed in human embryonic kidney 293 cells and *Xenopus laevis* oocytes. *J. Neurosci.* 19, 7426–7433
- Krautwurst, D. *et al.* (1998) Identification of ligands for olfactory receptors by functional expression of a receptor library. *Cell* 95, 917–926
- Katada, S. *et al.* (2004) Structural determinants for membrane trafficking and G protein selectivity of a mouse olfactory receptor. *J. Neurochem.* 90, 1453–1463
- Lin, X. *et al.* (1998) Addition of catfish gonadotropin-releasing hormone (GnRH) receptor intracellular carboxyl-terminal tail to rat GnRH receptor alters receptor expression and regulation. *Mol. Endocrinol.* 12, 161–171
- Ulloa-Aguirre, A. *et al.* (2006) G-protein-coupled receptor trafficking: understanding the chemical basis of health and disease. *ACS Chem. Biol.* 1, 631–638
- Kaupmann, K. *et al.* (1997) Expression cloning of GABA_B receptors uncovers similarity to metabotropic glutamate receptors. *Nature* 386, 239–246
- Couve, A. *et al.* (1998) Intracellular retention of recombinant GABA_B receptors. *J. Biol. Chem.* 273, 26361–26367
- Calver, A.R. *et al.* (2001) The C-terminal domains of the GABA_B receptor subunits mediate intracellular trafficking but are not required for receptor signaling. *J. Neurosci.* 21, 1203–1210
- Margeta-Mitrovic, M. *et al.* (2000) A trafficking checkpoint controls GABA_B receptor heterodimerization. *Neuron* 27, 97–106
- Pagano, A. *et al.* (2001) C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA_B receptors. *J. Neurosci.* 21, 1189–1202
- Michelsen, K. *et al.* (2005) Hide and run. Arginine-based endoplasmic-reticulum-sorting motifs in the assembly of heteromultimeric membrane proteins. *EMBO Rep.* 6, 717–722
- Margeta-Mitrovic, M. *et al.* (2001) Ligand-induced signal transduction within heterodimeric GABA_B receptor. *Proc. Natl. Acad. Sci. U. S. A.* 98, 14643–14648
- Margeta-Mitrovic, M. *et al.* (2001) Function of GB1 and GB2 subunits in G protein coupling of GABA_B receptors. *Proc. Natl. Acad. Sci. U. S. A.* 98, 14649–14654
- Couve, A. *et al.* (2001) Association of GABA_B receptors and members of the 14-3-3 family of signaling proteins. *Mol. Cell. Neurosci.* 17, 317–328
- Pupo, A.S. *et al.* (2003) N-terminal truncation of human α_{1D} -adrenoceptors increases expression of binding sites but not protein. *Eur. J. Pharmacol.* 462, 1–8
- Hague, C. *et al.* (2004) The N terminus of the human α_{1D} -adrenergic receptor prevents cell surface expression. *J. Pharmacol. Exp. Ther.* 309, 388–397

- 27 Wellendorph, P. and Brauner-Osborne, H. (2004) Molecular cloning, expression, and sequence analysis of GPCR6A, a novel family C G-protein-coupled receptor. *Gene* 335, 37–46
- 28 Wellendorph, P. *et al.* (2005) Deorphanization of GPCR6A: a promiscuous L- α -amino acid receptor with preference for basic amino acids. *Mol. Pharmacol.* 67, 589–597
- 29 Hall, R.A. and Lefkowitz, R.J. (2002) Regulation of G protein-coupled receptor signaling by scaffold proteins. *Circ. Res.* 91, 672–680
- 30 Brady, A.E. and Limbird, L.E. (2002) G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. *Cell. Signal.* 14, 297–309
- 31 Bockaert, J. *et al.* (2004) GPCR-interacting proteins (GIPs): nature and functions. *Biochem. Soc. Trans.* 32, 851–855
- 32 Prinster, S.C. *et al.* (2005) Heterodimerization of g protein-coupled receptors: specificity and functional significance. *Pharmacol. Rev.* 57, 289–298
- 33 Marshall, F.H. *et al.* (1999) GABA_B receptors function as heterodimers. *Biochem. Soc. Trans.* 27, 530–535
- 34 Gassmann, M. *et al.* (2004) Redistribution of GABA_{B(1)} protein and atypical GABA_B responses in GABA_{B(2)}-deficient mice. *J. Neurosci.* 24, 6086–6097
- 35 Hague, C. *et al.* (2004) Cell surface expression of α 1D-adrenergic receptors is controlled by heterodimerization with α 1B-adrenergic receptors. *J. Biol. Chem.* 279, 15541–15549
- 36 Uberti, M.A. *et al.* (2003) Subtype-specific dimerization of α 1-adrenoceptors: effects on receptor expression and pharmacological properties. *Mol. Pharmacol.* 64, 1379–1390
- 37 Uberti, M.A. *et al.* (2005) Heterodimerization with β 2-adrenergic receptors promotes surface expression and functional activity of α 1D-adrenergic receptors. *J. Pharmacol. Exp. Ther.* 313, 16–23
- 38 Bush, C.F. *et al.* (2007) Specificity of olfactory receptor interactions with other G protein-coupled receptors. *J. Biol. Chem.* 282, 19042–19051
- 39 Hague, C. *et al.* (2004) Olfactory receptor surface expression is driven by association with the β 2-adrenergic receptor. *Proc. Natl. Acad. Sci. U. S. A.* 101, 13672–13676
- 40 Bachmanov, A.A. and Beauchamp, G.K. (2007) Taste receptor genes. *Annu. Rev. Nutr.* 27, 389–414
- 41 Shieh, B.H. *et al.* (1989) The *ninaA* gene required for visual transduction in *Drosophila* encodes a homologue of cyclosporin A-binding protein. *Nature* 338, 67–70
- 42 Baker, E.K. *et al.* (1994) The cyclophilin homolog NinaA functions as a chaperone, forming a stable complex *in vivo* with its protein target rhodopsin. *EMBO J.* 13, 4886–4895
- 43 Ferreira, P.A. *et al.* (1996) Cyclophilin-related protein RanBP2 acts as chaperone for red/green opsin. *Nature* 383, 637–640
- 44 Dwyer, N.D. *et al.* (1998) Odorant receptor localization to olfactory cilia is mediated by ODR-4, a novel membrane-associated protein. *Cell* 93, 455–466
- 45 Gimelbrant, A.A. *et al.* (2001) Olfactory receptor trafficking involves conserved regulatory steps. *J. Biol. Chem.* 276, 7285–7290
- 46 Lehman, C.W. *et al.* (2005) Ubiquitously expressed GPCR membrane-trafficking orthologs. *Genomics* 85, 386–391
- 47 Chen, C. *et al.* (2006) GEC1 interacts with the κ opioid receptor and enhances expression of the receptor. *J. Biol. Chem.* 281, 7983–7993
- 48 Chen, Y. *et al.* (2009) GEC1- κ opioid receptor binding involves hydrophobic interactions: GEC1 has chaperone-like effect. *J. Biol. Chem.* 284, 1673–1685
- 49 Parent, A. *et al.* (2008) RACK1 regulates the cell surface expression of the G protein-coupled receptor for thromboxane A₂. *Traffic* 9, 394–407
- 50 Milojevic, T. *et al.* (2006) The ubiquitin-specific protease Usp4 regulates the cell surface level of the A_{2A} receptor. *Mol. Pharmacol.* 69, 1083–1094
- 51 Wruck, C.J. *et al.* (2005) Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. *Arterioscl. Thromb. Vasc. Biol.* 25, 57–64
- 52 Leclerc, P.C. *et al.* (2002) A polyaromatic caveolin-binding-like motif in the cytoplasmic tail of the type 1 receptor for angiotensin II plays an important role in receptor trafficking and signaling. *Endocrinology* 143, 4702–4710
- 53 McLatchie, L.M. *et al.* (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* 393, 333–339
- 54 Bouschet, T. *et al.* (2005) Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. *J. Cell Sci.* 118, 4709–4720
- 55 Hay, D.L. *et al.* (2006) GPCR modulation by RAMPs. *Pharmacol. Ther.* 109, 173–197
- 56 Saito, H. *et al.* (2004) RTP family members induce functional expression of mammalian odorant receptors. *Cell* 119, 679–691
- 57 Behrens, M. *et al.* (2006) Members of RTP and REEP gene families influence functional bitter taste receptor expression. *J. Biol. Chem.* 281, 20650–20659
- 58 Decaillot, F.M. *et al.* (2008) Cell surface targeting of μ - δ opioid receptor heterodimers by RTP4. *Proc. Natl. Acad. Sci. U. S. A.* 105, 16045–16050
- 59 Metherell, L.A. *et al.* (2005) Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. *Nat. Genet.* 37, 166–170
- 60 Roy, S. *et al.* (2007) Differential regulation of the human adrenocorticotropin receptor [melanocortin-2 receptor (MC2R)] by human MC2R accessory protein isoforms α and β in isogenic human embryonic kidney 293 cells. *Mol. Endocrinol.* 21, 1656–1669
- 61 Hinkle, P.M. and Sebag, J.A. (2009) Structure and function of the melanocortin2 receptor accessory protein (MRAP). *Mol. Cell. Endocrinol.* 300, 25–31
- 62 Sebag, J.A. and Hinkle, P.M. (2009) Regions of melanocortin 2 (MC2) receptor accessory protein necessary for dual topology and MC2 receptor trafficking and signaling. *J. Biol. Chem.* 284, 610–618
- 63 Chan, L.F. *et al.* (2009) MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. *Proc. Natl. Acad. Sci. U. S. A.* 106, 6146–6151
- 64 Loconto, J. *et al.* (2003) Functional expression of murine V2R pheromone receptors involves selective association with the M10 and M1 families of MHC class Ib molecules. *Cell* 112, 607–618
- 65 Bernier, V. *et al.* (2004) Pharmacological chaperone action on G-protein-coupled receptors. *Curr. Opin. Pharmacol.* 4, 528–533
- 66 Conn, P.M. *et al.* (2007) G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue *in vivo*. *Pharmacol. Rev.* 59, 225–250
- 67 Bernier, V. *et al.* (2004) Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. *Mol. Endocrinol.* 18, 2074–2084
- 68 Morello, J.P. *et al.* (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. *J. Clin. Invest.* 105, 887–895
- 69 Wuller, S. *et al.* (2004) Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. *J. Biol. Chem.* 279, 47254–47263
- 70 Robben, J.H. *et al.* (2007) Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. *Am. J. Physiol. Renal Physiol.* 292, F253–260
- 71 Bernier, V. *et al.* (2006) Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. *J. Am. Soc. Nephrol.* 17, 232–243
- 72 Dejneka, N.S. and Bennett, J. (2001) Gene therapy and retinitis pigmentosa: advances and future challenges. *Bioessays* 23, 662–668
- 73 Dryja, T.P. *et al.* (1990) Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. *N. Engl. J. Med.* 323, 1302–1307
- 74 Dryja, T.P. *et al.* (1990) A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. *Nature* 343, 364–366
- 75 Sung, C.H. *et al.* (1991) Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. *Proc. Natl. Acad. Sci. U. S. A.* 88, 8840–8844
- 76 Noorwez, S.M. *et al.* (2003) Pharmacological chaperone-mediated *in vivo* folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. *J. Biol. Chem.* 278, 14442–14450
- 77 Janovick, J.A. *et al.* (2003) Structure–activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. *J. Pharmacol. Exp. Ther.* 305, 608–614
- 78 Janovick, J.A. *et al.* (2002) Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. *J. Clin. Endocrinol. Metab.* 87, 3255–3262